Mylan settles cancer drug patent dispute with Genentech
15-03-2017
warchi / iStockphoto.com
Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
oncology, cancer, cancer therapy, Chugai Pharmaceuticals, Nippon Kayaku, Roche, Genentech, Tokyo District Court
